ArticleAllergy, asthma & immunology research2025
Neuromedin U Activation of Group 2 Innate Lymphocytes Exacerbates Local Inflammation of Nasal Mucosa in Allergic Rhinitis.
Article in Allergy, asthma & immunology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- γδ T Cell-Mediated Neuroimmune Interactions in Skin Inflammation and Allergy.Clinical reviews in allergy & immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAllergic rhinitis (AR) is no longer considered an immune dysregulation disorder but rather a neuroimmune disorder regulated by neuronal signals. However, the mechanisms underlying these effects remain unclear. Therefore, we evaluated whether the local nasal mucosa is regulated by neuroimmune signals during nasal allergic reactions.
methodsWe identified genes that were differentially expressed between patients with AR and healthy controls using GSE46171 gene chip data. Expression levels of neuromedin U (NMU), NMU receptor 1 (NMUR1), and group 2 innate lymphoid cells (ILC2s) in the nasal mucosa were determined the impacts of NMU on patients with AR were assessed. An AR animal model was established to observe the effects of local NMU intervention on local and systemic ILC2s in the nasal cavity.
resultsWe identified 1,137 differentially expressed genes and focused on the neuropeptide NMU. NMU was widely distributed in the lamina propria of the nasal mucosa of patients with AR. NMUR1 was expressed at high levels in the lamina propria, basal layer, and glandular epithelium. Local ILC2 expression in the nasal mucosa of the AR group was elevated and positively correlated with NMU and NMUR1 expression. Using the AR model, we found that NMU significantly enhanced both local and systemic inflammatory responses in ovalbumin-sensitized mice and promoted activation of ILC2s to release additional type 2 inflammatory cytokines. However, this effect was blocked by an extracellular signal-regulated kinase (ERK) pathway inhibitor, indicating that NMU activates ILC2s via the ERK pathway, contributing to AR pathogenesis.
conclusionsDuring nasal allergic reactions, local NMU increases significantly in the nasal cavity, activating ILC2s via the ERK pathway to release type 2 cytokines, thereby participating in or exacerbating the onset of AR. These findings lay the groundwork for exploration of diverse factors that contribute to AR and suggest new approaches to prevention and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.